8.855

3.59% -0.335

Upstream Bio Inc (UPB)

Overview News Price History Discussions Forecast

Upstream Bio Inc stock is traded at $8.855, with a volume of 129.12K. It is down -3.59% in the last 24 hours and down -8.66% over the past month. Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).

Previous Close:

$9.19

Open:

$9.14

24h Volume:

129.12K

Relative Volume:

0.11

Market Cap:

$481.49M

Revenue:

$2.85M

Net Income/Loss:

$-143.44M

P/E Ratio:

-3.3249

EPS:

-2.6632

Net Cash Flow:

$-133.44M

1W Performance:

-3.49%

1M Performance:

-8.66%

6M Performance:

-61.41%

1Y Performance:

+3.26%

1-Day Range:

$8.69

$9.14

1-Week Range:

$8.69

$9.57

52-Week Range:

$7.25

$33.68

Upstream Bio Inc Stock (UPB) Company Profile

Name

Upstream Bio Inc

Sector

Healthcare (1115)

Industry

Biotechnology (621)

Phone

781-208-2466

Address

890 WINTER STREET, SUITE 200, WALTHAM

Employee

Twitter

Next Earnings Date

2026-05-05

Latest SEC Filings

UPB's Discussions on Twitter

Compare UPB vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
UPB Upstream Bio Inc	8.8477	500.12M	2.85M	-143.44M	-133.44M	-2.6632
VRTX Vertex Pharmaceuticals Inc	426.44	108.54B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	711.31	75.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	782.00	50.22B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	294.95	40.45B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	315.66	32.51B	5.36B	287.73M	924.18M	2.5229

Upstream Bio Inc Stock (UPB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-26	Downgrade	Evercore ISI	Outperform → In-line
Dec-18-25	Initiated	Mizuho	Outperform
Nov-18-25	Initiated	Evercore ISI	Outperform
Oct-14-25	Initiated	Truist	Buy
Nov-05-24	Initiated	JP Morgan	Overweight
Nov-05-24	Initiated	Piper Sandler	Overweight
Nov-05-24	Initiated	TD Cowen	Buy
Nov-05-24	Initiated	William Blair	Outperform

View All

Upstream Bio Inc Stock (UPB) Latest News

May 03, 2026

Jennison Associates LLC Makes New Investment in Upstream Bio, Inc. $UPB - MarketBeat

May 03, 2026

May 01, 2026

UPB Forecast, Price Target & Analyst Ratings | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill

Apr 28, 2026

Apr 24, 2026

Segment Overview and Major Growth Areas in the Upstream Bioprocessing Market - openPR.com

Apr 24, 2026

Apr 23, 2026

Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.

Apr 23, 2026

Apr 22, 2026

Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Apr 22, 2026

Apr 20, 2026

Upstream Bio (UPB) Stock Bonus Issue (Bearish Sentiment) 2026-04-20Bullish Pattern - Newser

Apr 20, 2026

Apr 18, 2026

Upstream Bio (UPB) Stock Ask Wall (Trend Weakens) 2026-04-18Upside Potential - Cổng thông tin điện tử tỉnh Lào Cai

Apr 18, 2026

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference - Sahm

Apr 18, 2026

Apr 17, 2026

Upstream Bio to present verekitug data at medical conference By Investing.com - Investing.com Australia

Apr 17, 2026

Upstream Bio to present verekitug data at medical conference - Investing.com

Apr 17, 2026

Apr 13, 2026

Can Upstream Bio (UPB) Stock Beat Estimates | Price at $10.24, Down 2.38%AI Stock Signals - Newser

Apr 13, 2026

Bull Bear: Is Upstream Bio Inc a cyclical or defensive stock2026 Intraday Action & Low Drawdown Trading Strategies - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

UPB Options Volatility — NASDAQ:UPB - TradingView — Track All Markets

Apr 11, 2026

UPB Options Chain — NASDAQ:UPB - TradingView

Apr 11, 2026

Apr 07, 2026

Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward - TipRanks

Apr 07, 2026

Apr 06, 2026

Earnings Update: Is Upstream Bio Inc still a buy after recent gains2026 Rallies & Reliable Entry Point Trade Alerts - baoquankhu1.vn

Apr 06, 2026

Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and Pfizer (PFE) - The Globe and Mail

Apr 06, 2026

Apr 02, 2026

Truist cuts Upstream Bio stock price target on trial timeline By Investing.com - Investing.com Canada

Apr 02, 2026

Market Recap: Is Upstream Bio Inc forming a bullish divergence2026 Volume & Daily Chart Pattern Signals - baoquankhu1.vn

Apr 02, 2026

Piper Sandler Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $75 - Moomoo

Apr 02, 2026

Apr 01, 2026